top of page
NEWS
Picture1.png

Laval, QC, April 4, 2024 - Morphocell Technologies proudly announces the closure of a US$40 million Series A financing round. This significant financial milestone, led by Genson Capital, is set to fuel the company’s groundbreaking journey towards a first-in-human clinical trial.

CH_headshot.jpg

Montreal, QC, January 17, 2024 – Morphocell Technologies is thrilled to announce the appointment of Dr. Calley Hirsch as its new Vice President Preclinical Development

Panos.png

Montreal, QC, July 24, 2023 – Morphocell Technologies is excited to announce the appointment of Dr. Panos Chrysanthopoulos as its new Chief Development Officer

5e36ccea-513b-4091-8790-59f9d697466a.png

Morphocell will present its progress, platform and preclinical data at Biotech Showcase 2023, one of the most important investor conferences, in San Francisco, CA.

cover2_iPSC-derived hepatocyte-like cells_CK18-DAPI.png

Morphocell Technologies announces the publication of an innovative, scalable method for generating high-quality liver cells from induced pluripotent stem cells. 

i_blad_blue.png

The US Patent Office (USPTO) has granted Morphocell Technologies patent number US11096388 covering the use of its Encapsulated Liver Tissue as part of a Bioartificial Liver Device

AdobeStock_158894132.jpeg

Morphocell Technologies, CQDM and Takeda Pharmaceutical Company Limited, with support from the Stem Cell Network, came together to fund a $979,200 Quantum Leap project that will enable Morphocell to generate preclinical efficacy and safety data in large animals for ReLiver®ELT

BIO2021-Lockup-navy.png

Morphocell has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.

STEMCELL_logo_Bilingual-Colour.jpg

Morphocell Technologies’ quest to transform the treatment of liver disease took another major step forward today with the announcement of new Stem Cell Network  (SCN) funding for the Paganelli lab at Le Centre hospitalier universitaire Sainte-Justine. 

Bennilover 2020 image.jpg

The Morphocell team is gearing up for a busy and exciting 2020, starting with our participation at two can’t-miss conferences.

Jennifercrop.jpg

Stem cell commercialization expert Dr. Jennifer Moody appointed Chief Operating Officer beginning October 7th, 2019.

mitosis_crop.jpg

Morphocell Technologies Inc. held a successful pre-pre-Clinical Trial Application (CTA) meeting with Health Canada in August 2019.

maggie.png

Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. She will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations.

Organoid_marie_5_low.jpg

Morphocell Technologies signs exclusive license for the commercialisation of innovative stem cell-derived Encapsulated Liver Tissue technology.

bottom of page